Anti-PD-1 inhibitor-related pneumonitis in non-small cell lung cancer

Cancer Immunology Research

Volumn 4, Issue 4, 2016, Pages 289-293

  Nishino, Mizuki ^a   Chambers, Emily S ^a   Chong, Curtis R ^a   Ramaiya, Nikhil H ^a   Gray, Stacy W ^a   Marcoux, J Paul ^a   Hatabu, Hiroto ^a   Jänne, Pasi A ^a   Hodi, F Stephen ^a   Awad, Mark M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; COTRIMOXAZOLE; LEVOFLOXACIN; NIVOLUMAB; PACLITAXEL; PREDNISONE; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PREDNISOLONE; PROGRAMMED DEATH 1 RECEPTOR;

ADVANCED CANCER; AGED; ARTICLE; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; CANCER SIZE; CANCER SURGERY; CASE REPORT; CONSOLIDATION; COUGHING; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; GROUND GLASS OPACITY; HUMAN; HYPOXEMIA; LIVER METASTASIS; LUNG LOBECTOMY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; PNEUMOCYSTIS PNEUMONIA; RADIOLOGICAL PARAMETERS; RETICULAR OPACITY; RETREATMENT; RETROSPECTIVE STUDY; SYSTEMIC THERAPY; VERY ELDERLY; WHEEZING; X-RAY COMPUTED TOMOGRAPHY; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; COMPLICATION; LUNG NEOPLASMS; PNEUMONIA; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; PNEUMONIA; PREDNISOLONE; PROGRAMMED CELL DEATH 1 RECEPTOR; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 85016477912     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-15-0267     Document Type: Article

References (16)

1. Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, et al. Overall survival and long-term safety of nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in patients with previously treated advancednon-small-cell lung cancer. J ClinOncol 2015;33:2004-12.
2. Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumabrefractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial. Lancet Oncol 2015;16:908-18.
3. Rizvi NA, Mazieres J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): A phase 2, single-arm trial. Lancet Oncol 2015;16:257-65.
4. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Antiprogrammed- death-receptor-1 treatment with pembrolizumab in ipilimumab- refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial. Lancet 2014;384:1109-17.
5. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
6. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014;32:1020-30.
7. Nishino M, Tirumani SH, Ramaiya NH, Hodi FS. Cancer immunotherapy and immune-related response assessment: the role of radiologists in the new arena of cancer treatment. Eur J Radiol 2015;84:1259-68.
8. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-smallcell lung cancer. N Engl J Med 2015;373:123-35.
9. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015;373:1627-39.
10. Garon EB, Rizvi NA, Hui R, Leighl N, Balman oukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372:2018-28.
11. Nishino M, Sholl LM, Hodi FS, Hatabu H, Ramaiya NH. Anti-PD-1- related pneumonitis during cancer immunotherapy. N Engl JMed 2015; 373:288-90.
12. Nishino M, Boswell EN, Hatabu H, Ghobrial IM, Ramaiya NH. Drug-related pneumonitis during mammalian target of rapamycin inhibitor therapy: radiographic pattern-based approach in Waldenström macroglobulinemia as a paradigm. Oncologist 2015;20:1077-83.
13. Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013; 188:733-48.
14. Kim SJ, Lee KS, Ryu YH, Yoon YC, Choe KO, Kim TS, et al. Reversed halo sign on high-resolution CT of cryptogenic organizing pneumonia: diagnostic implications. AJR Am J Roentgenol 2003;180:1251-4.
15. Horvat TZ, Adel NG, Dang TO, Momtaz P, Postow MA, Callahan MK, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol 2015;33:3193-8.
16. NishinoM, Cardarella S, Dahlberg SE, Araki T, Lydon C, Jackman DM, et al. Interstitial lung abnormalities in treatment-naive advanced non-small-cell lung cancer patients are associated with shorter survival. Eur J Radiol 2015;84:998-1004.